• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

1-5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-ol (CAS No. 1202805-26-2): A Comprehensive Overview

1-5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-ol (CAS No. 1202805-26-2) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, commonly referred to as a boronic ester derivative, plays a crucial role in various chemical reactions and biological processes. Its unique structure and properties make it an essential tool in the development of novel therapeutic agents and the exploration of new biological pathways.

The chemical structure of 1-5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-ol is characterized by a pyrimidine ring linked to a piperidine ring through a boronic ester moiety. The presence of the boronic ester group imparts unique reactivity and selectivity to the molecule, making it highly valuable in synthetic organic chemistry. The tetramethyl dioxaborolane substituent enhances the stability and solubility of the compound, facilitating its use in various chemical transformations.

In recent years, 1-5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-ol has been extensively studied for its potential applications in drug discovery and development. One of the key areas of interest is its use as a building block in the synthesis of boron-containing drugs. Boron-based compounds have shown promise in treating various diseases, including cancer and inflammatory disorders. The ability to incorporate boron into drug molecules can enhance their pharmacological properties, such as target specificity and bioavailability.

A notable example of the application of 1-5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-ol is in the development of targeted therapies for cancer. Research has demonstrated that this compound can be used to synthesize boronated prodrugs that selectively accumulate in tumor tissues. Once inside the tumor, these prodrugs can be activated by specific enzymes or conditions, releasing active drug molecules that exert their therapeutic effects. This approach has the potential to improve treatment outcomes while minimizing side effects on healthy tissues.

Beyond its use in drug synthesis, 1-5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-ol has also been explored for its biological activities. Studies have shown that this compound exhibits anti-inflammatory properties by modulating key signaling pathways involved in inflammation. For instance, it can inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are known to play a central role in chronic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease.

The versatility of 1-5-(Tetramethyl-1,3,2-dioxaborolan-2-y l)pyrimidin - 2 - ylpiperidin - 4 - ol extends to its use as a ligand in metal-catalyzed reactions. The boronic ester group can coordinate with transition metals such as palladium and nickel, enabling efficient cross-coupling reactions that are crucial for the synthesis of complex organic molecules. This property makes it an indispensable reagent in synthetic chemistry laboratories worldwide.

In addition to its synthetic applications, 1 - 5 - (Tetramethyl - 1 , 3 , 2 - dioxaborolan - 2 - yl ) pyrimidin - 2 - ylpiperidin - 4 - ol has been investigated for its potential as a radiopharmaceutical precursor. Boron-containing compounds can be labeled with positron-emitting isotopes such as carbon-11 or fluorine–18 for use in positron emission tomography (PET) imaging. This allows researchers to visualize and quantify the distribution of these compounds in living organisms, providing valuable insights into their pharmacokinetics and biodistribution.

The safety profile of 1 - 5 - (Tetramethyl - 1 , 3 , 2 - dioxaborolan - 2 - yl ) pyrimidin - 2 - ylpiperidin - 4 - ol is another important aspect that has been extensively studied. Preclinical studies have shown that this compound exhibits low toxicity and good biocompatibility when administered at therapeutic doses. These findings support its potential for further development as a safe and effective therapeutic agent.

In conclusion, 1 - 5 - (Tetramethyl - 1 , 3 , 2 - dioxaborolan - 2 - yl ) pyrimidin - 2 - ylpiperidin - 4 - ol (CAS No. 1202805–26–7) is a multifaceted compound with significant potential in various areas of medicinal chemistry and pharmaceutical research. Its unique chemical structure and properties make it an invaluable tool for developing novel drugs and exploring new biological pathways. As research continues to advance, it is likely that this compound will play an increasingly important role in the discovery and development of innovative therapies for a wide range of diseases.

• 1402174-21-3(Pyrimidine, 2-(4-methyl-1-piperidinyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-)
• 1202805-30-8({1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-4-yl}methanol)
• 1402166-41-9(1-(5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)pyrimidin-2-yl)pyrrolidin-3-ol)
• 1355388-42-9(1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-3-ol)
• 1015242-05-3(1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]azepane)
• 1015242-08-6(2-(3,4-Dihydropyridin-1(2H)-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 1421325-54-3({1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpyrrolidin-3-yl}methanol)
• 1448172-67-5(2-(Azetidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 1202805-21-7({1-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-ylpiperidin-3-yl}methanol)
• 1015242-07-5(-(pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)